CrossAssetDataThe Company File
···
XERS

Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in Chicago, IL. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $292 million and a profit of $554 thousand (its filed statements).

Product business Pharmaceutical Preparations Chicago, IL filings since 2021 8 of 9 filed, 1 estimated
Ask the desk about XERS → Compare XERS with KMDA → Price chart on TradingView ↗ Full EDGAR file ↗ Watch XERS →

Sector peers: KMDATRDAAKBAIRWD

5.8/10headline grade
vs its business-model standard
7.0/10past 5.4/10present 5.1/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 2834, Pharmaceutical Preparations); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 5.8 out of ten, 8 of 9 metrics filed and 1 estimated: past 7.0 out of ten, present 5.4 out of ten, future 5.1 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 6.2 out of ten. 1 warning event since 2021; the latest 2023-03-17. 61st percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 8.4 out of ten. +70.7% a year over 6 filed years; profitable in 1 of 6. 84th percentile among 324 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 5.5 out of ten. CrossAssetData estimate 5.5/10, confidence 35 of 100 (one part). 56th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 5.0 out of ten. ROE 4%: 4¢ of profit per shareholder dollar. Leverage 96%: owes 96¢ per asset dollar. 50th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 7.5 out of ten. top 25% of 314 in its family; net margin 0.2%. 75th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 3.4 out of ten. bottom 34% of 315 in its family for leadership; chief executive since 2024. 34th percentile among 315 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 3.3 out of ten. bottom 33% of 272 in its family for room to expand. 33rd percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 6.3 out of ten. top 37% of 307 in its family for growth drivers. 63rd percentile among 307 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 7.0 out of ten. top 30% of 234 in its family for expectations against reality. 70th percentile among 234 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-03-02 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-06 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-06 (on EDGAR). Newest filing: Form 4, 2026-10-02. Filings on record since 2021. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Recorlev 48%, Gvoke 32%, Keveyis 16%, Royalty Contract and Other Revenue 3%, Product Other 1%. As tagged in its annual report (Form 10-K, filed 2026-03-02).

Who runs it

Shannon, John Patrick Jr (Chief Executive Officer and Chairman of the Board); Nguyen, Anh Tu (Chief Medical Officer); Hecht, Beth (See Remarks); Mcculloch, Kevin (See Remarks); Pieper, Steven (See Remarks); Kreher, Nerissa (director); Bormann-Kennedy, Barbara-Jean Anne (director); Brady, James Aloysius (director); Halkuff, Dawn (director); Johnson, John (director); and 3 more. 13 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-02.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.